Chemical Nameansuvimab-zykl
Dosage FormInjection (intravenous; 400 mg lyophilized powder in a single-dose vial for reconstitution and further dilution)
Drug ClassMonoclonal antibodies
CompanyRidgeback Biotherapeutics
Approval Year2020


  • Indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
Last updated on 1/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ebanga (ansuvimab) Prescribing Information.2020Ridgeback Biotherapeutics, LP, Miami, FL
Document TitleYearSource
A randomized, controlled trial of Ebola virus disease therapeutics.2020The New England Journal of Medicine